<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451958</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS21A</org_study_id>
    <secondary_id>2006-006913-34</secondary_id>
    <nct_id>NCT00451958</nct_id>
  </id_info>
  <brief_title>A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy</brief_title>
  <official_title>An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients With Prostate Cancer Requiring Androgen Ablation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486
      CS21A study. The study continued until all non-discontinued participants had received
      treatment for at least 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight</measure>
    <time_frame>Up to 4 years of treatment</time_frame>
    <description>This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline (from main CS21 study, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables</measure>
    <time_frame>Up to 4 years of treatment</time_frame>
    <description>This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline (from main CS21 trial, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A. Only the laboratory variables that had at least five percentages of participants in either group with abnormal value are presented, more variables were included in the study. ULN=Upper limit of normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Prostate-specific Antigen (PSA) Progression</measure>
    <time_frame>Until all participants have received at least 5 years of treatment and at a frequency of every 3 months</time_frame>
    <description>PSA progression was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir (obtained in either CS21, NCT00295750, or CS21A). The figures below present the percentage of participants with no PSA progression at each of the selected time points (there were more time points in the study) along with corresponding 95% confidence intervals (CI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Testosterone Level Maintained at &lt;=0.5 ng/mL From Day 28 in CS21 and Onwards</measure>
    <time_frame>Until all participants have received at least 5 years of treatment and at a frequency of every 6 months</time_frame>
    <description>The results below present the percentage of participants of having testosterone &lt;=0.5 ng/mL at each of the selected time points (there were more time points in the study) from Day 28 in CS21 (NCT00295750) until the end of the CS21A study.
In all treatment groups approximately 3% per year of the participants had at least one testosterone &gt;0.5 ng/mL during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Testosterone From the Time of Switch From Leuprolide to Degarelix up to Day 56</measure>
    <time_frame>From time of switch to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of PSA From the Time of Switch From Leuprolide to Degarelix to Day 56</measure>
    <time_frame>From time of switch to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56</measure>
    <time_frame>From time of switch to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Follicle Stimulating Hormone (FSH) From the Time of Switch From Leuprolide to Degarelix to Day 56</measure>
    <time_frame>From time of switch to Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix 80 mg / Degarelix 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 160 mg / Degarelix 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprolide 7.5 mg / Degarelix 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprolide 7.5 mg / Degarelix 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 80 mg / Degarelix 80 mg</intervention_name>
    <arm_group_label>Degarelix 80 mg / Degarelix 80 mg</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix 160 mg / Degarelix 160 mg</intervention_name>
    <arm_group_label>Degarelix 160 mg / Degarelix 160 mg</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide 7.5 mg / Degarelix 80 mg</intervention_name>
    <arm_group_label>Leuprolide 7.5 mg / Degarelix 80 mg</arm_group_label>
    <other_name>Firmagon</other_name>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide 7.5 mg / Degarelix 160 mg</intervention_name>
    <arm_group_label>Leuprolide 7.5 mg / Degarelix 160 mg</arm_group_label>
    <other_name>Firmagon</other_name>
    <other_name>Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion/Exclusion Criteria:

          -  Patients with histologically proven prostate cancer of all stages in whom endocrine
             treatment is indicated.

          -  Signed informed consent

          -  The patients must have completed the FE 200486 CS21 Study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology Centers Of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Orange County Medical Research Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Associates Research</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville Urology</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Carmel</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Urology Research</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State College Urologic Association</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Urology Research Center</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Female/Male Health Centres</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burlington Professional Centre</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Research Centre</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Female/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology South Shore Research</name>
      <address>
        <city>Greenfields</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Can-Med Clinical Research Inc</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UROHELP - Bozetechova</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jindrichuv Hradec, a.s.</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slezska nemocnice</name>
      <address>
        <city>Opava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole, Prague5</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze, Prague2</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim Universitätsklinikum GmbH</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fövárosi Önkormányzat uzsoki utcai Kórház</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dombóvári Szent Lukács Egészségügyi Kht.</name>
      <address>
        <city>Dombóvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Megyei Oktató Kórház</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pécsi Tudományegyetem</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Acapulco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Christus Muguerza del Parque</name>
      <address>
        <city>Chihuahua, Chih.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Sit</name>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aranda de la Parra , S.A. de C.V.</name>
      <address>
        <city>Leon, GTO</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico, DF Mexico</name>
      <address>
        <city>Mexico, DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mexico, DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Andres Grillasca</name>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Uronephrology and Renal Transplant Clinical Institute</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sfantul Ioan&quot; Emergency Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PROVITA 2000 Medical Center</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibiu Emergency Clinical County Hospital</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1 n.a. N.I.Pirogov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #60</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Pokrovskaya Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Medical Academy n. a. I.I.Mechnikov</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk State Medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #3</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa State Medical University</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre For Oncology</name>
      <address>
        <city>Bebington, Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2007</study_first_submitted>
  <study_first_submitted_qc>March 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2007</study_first_posted>
  <results_first_submitted>October 10, 2012</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2013</results_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Degarelix</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants who completed the CS21 study (NCT00295750) were eligible to enrol into the CS21A extension study. Since the number of participants who completed this long-term study was low, no firm conclusions can be drawn from the results.</recruitment_details>
      <pre_assignment_details>Initially, participants treated with degarelix during CS21 continued to treatment and patients who received treatment with leuprolide during CS21 were re-randomised to one of the two degarelix treatment regimens. Following a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg for the rest of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 80 mg / Degarelix 80 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 of the CS21 study (NCT00295750) as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the CS21 study and the current CS21A study.</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 160 mg / Degarelix 160 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 of the CS21 study (NCT00295750) as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the CS21 study and the current CS21A study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="P3">
          <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
          <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="P4">
          <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
          <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="P5">
          <title>Leuprolide 7.5 mg</title>
          <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
When the main CS21 study was completed these patients were switched to treatment with degarelix 80 mg or 160 mg in the CS21A study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>CS21 (NCT00295750)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210">CS21 intention-to-treat (ITT) population.</participants>
                <participants group_id="P2" count="206">CS21 ITT population.</participants>
                <participants group_id="P3" count="0">Participants were switched from the leuprolide 7.5 mg group when CS21 was completed.</participants>
                <participants group_id="P4" count="0">Participants were switched from the leuprolide 7.5 mg group when CS21 was completed.</participants>
                <participants group_id="P5" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>CS21A (NCT00451958)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125">CS21A intention-to-treat (ITT) population.</participants>
                <participants group_id="P2" count="126">CS21A ITT population.</participants>
                <participants group_id="P3" count="69">CS21A ITT population.</participants>
                <participants group_id="P4" count="66">One of the enrolled participants never received any treatment, i.e. the CS21A ITT population=65.</participants>
                <participants group_id="P5" count="0">Participants were switched to the degarelix groups when CS21 was completed.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous reasons</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>CS21A intention-to-treat (ITT) population.</population>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 80 mg / Degarelix 80 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 160 mg / Degarelix 160 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="B3">
          <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
          <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="B4">
          <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
          <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="385"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>CS21A intention-to-treat (ITT) population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="7.62"/>
                    <measurement group_id="B2" value="71.1" spread="8.25"/>
                    <measurement group_id="B3" value="72.4" spread="9.46"/>
                    <measurement group_id="B4" value="71.4" spread="8.24"/>
                    <measurement group_id="B5" value="71.1" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>CS21A ITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>CS21A ITT population.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <description>CS21A ITT population.</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" spread="12.6"/>
                    <measurement group_id="B2" value="79.2" spread="13.4"/>
                    <measurement group_id="B3" value="78.7" spread="11.3"/>
                    <measurement group_id="B4" value="80.0" spread="12.1"/>
                    <measurement group_id="B5" value="79.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>CS21A ITT population.</description>
          <units>kilogram per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.4" spread="3.92"/>
                    <measurement group_id="B2" value="26.9" spread="3.79"/>
                    <measurement group_id="B3" value="26.9" spread="3.94"/>
                    <measurement group_id="B4" value="27.1" spread="3.67"/>
                    <measurement group_id="B5" value="26.8" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>CS21A ITT population. The Gleason Score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive. Two of the participants did not have a Gleason Score at Baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gleason Score 2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason Score 5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason Score 7-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of Prostate Cancer</title>
          <description>CS21A ITT population. Prostate cancer stage was classified according to the Tumor, Nodes, and Metastatic (TNM) scale to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localised</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Testosterone Levels</title>
          <description>CS21A ITT population.</description>
          <units>nanograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.63" lower_limit="1.28" upper_limit="10.6"/>
                    <measurement group_id="B2" value="4.02" lower_limit="0.55" upper_limit="10.6"/>
                    <measurement group_id="B3" value="4.32" lower_limit="1.34" upper_limit="12.5"/>
                    <measurement group_id="B4" value="3.51" lower_limit="0.37" upper_limit="8.00"/>
                    <measurement group_id="B5" value="4.23" lower_limit="0.37" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Prostate-Specific Antigen (PSA) Levels</title>
          <description>CS21A ITT population.</description>
          <units>nanograms per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.2" lower_limit="1.70" upper_limit="3187"/>
                    <measurement group_id="B2" value="22.5" lower_limit="1.50" upper_limit="4902"/>
                    <measurement group_id="B3" value="25.5" lower_limit="1.60" upper_limit="2112"/>
                    <measurement group_id="B4" value="14.0" lower_limit="1.60" upper_limit="10952"/>
                    <measurement group_id="B5" value="21.0" lower_limit="1.50" upper_limit="10952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight</title>
        <description>This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline (from main CS21 study, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A.</description>
        <time_frame>Up to 4 years of treatment</time_frame>
        <population>The analysis population comprised all participants who were enrolled in the CS21A study and who received at least one dose of degarelix during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 80 mg / Degarelix 80 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 160 mg / Degarelix 160 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O4">
            <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight</title>
          <description>This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline (from main CS21 study, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A.</description>
          <population>The analysis population comprised all participants who were enrolled in the CS21A study and who received at least one dose of degarelix during the study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &gt;=105 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &lt;=90 and decrease &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &gt;=180 and increase &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &gt;=120 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight decrease of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight increase of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables</title>
        <description>This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline (from main CS21 trial, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A. Only the laboratory variables that had at least five percentages of participants in either group with abnormal value are presented, more variables were included in the study. ULN=Upper limit of normal.</description>
        <time_frame>Up to 4 years of treatment</time_frame>
        <population>The analysis population comprised all participants who were enrolled in the CS21A study and who received at least one dose of degarelix during the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 80 mg / Degarelix 80 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 160 mg / Degarelix 160 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O4">
            <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables</title>
          <description>This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline (from main CS21 trial, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A. Only the laboratory variables that had at least five percentages of participants in either group with abnormal value are presented, more variables were included in the study. ULN=Upper limit of normal.</description>
          <population>The analysis population comprised all participants who were enrolled in the CS21A study and who received at least one dose of degarelix during the study period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S-Potassium (mmol/L) &gt;=5.8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-Alanine aminotransferase (IU/L) &gt;3xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-Alkaline phosphatase (IU/L) &gt;3xULN+25% increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-Creatinine (µmol/L) &gt;=177</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-Urea nitrogen (mmol/L) &gt;=10.7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Haematocrit (Ratio) &lt;=0.37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Haemoglobin (g/L) &lt;=115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Red blood cell count (10^12/L) &lt;=3.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Eosinophils (%) &gt;=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Lymphocytes (%) &lt;=10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Prostate-specific Antigen (PSA) Progression</title>
        <description>PSA progression was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir (obtained in either CS21, NCT00295750, or CS21A). The figures below present the percentage of participants with no PSA progression at each of the selected time points (there were more time points in the study) along with corresponding 95% confidence intervals (CI).</description>
        <time_frame>Until all participants have received at least 5 years of treatment and at a frequency of every 3 months</time_frame>
        <population>CS21 ITT analysis set i.e. all participants who received at least one dose of degarelix or leuprolide during the mail study (CS21).</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 80 mg / Degarelix 80 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 160 mg / Degarelix 160 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O4">
            <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Prostate-specific Antigen (PSA) Progression</title>
          <description>PSA progression was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir (obtained in either CS21, NCT00295750, or CS21A). The figures below present the percentage of participants with no PSA progression at each of the selected time points (there were more time points in the study) along with corresponding 95% confidence intervals (CI).</description>
          <population>CS21 ITT analysis set i.e. all participants who received at least one dose of degarelix or leuprolide during the mail study (CS21).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="99.5" lower_limit="96.5" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.6" lower_limit="90.2" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="85.9" upper_limit="94.5"/>
                    <measurement group_id="O2" value="85.8" lower_limit="79.8" upper_limit="90.1"/>
                    <measurement group_id="O3" value="82.6" lower_limit="71.4" upper_limit="89.7"/>
                    <measurement group_id="O4" value="87.9" lower_limit="80.4" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1960</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" lower_limit="50.9" upper_limit="69.7"/>
                    <measurement group_id="O2" value="58.7" lower_limit="48.7" upper_limit="67.4"/>
                    <measurement group_id="O3" value="50.7" lower_limit="36.3" upper_limit="63.4"/>
                    <measurement group_id="O4" value="73.8" lower_limit="60.9" upper_limit="83.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Testosterone Level Maintained at &lt;=0.5 ng/mL From Day 28 in CS21 and Onwards</title>
        <description>The results below present the percentage of participants of having testosterone &lt;=0.5 ng/mL at each of the selected time points (there were more time points in the study) from Day 28 in CS21 (NCT00295750) until the end of the CS21A study.
In all treatment groups approximately 3% per year of the participants had at least one testosterone &gt;0.5 ng/mL during the study.</description>
        <time_frame>Until all participants have received at least 5 years of treatment and at a frequency of every 6 months</time_frame>
        <population>CS21 ITT analysis set i.e. all participants who received at least one dose of degarelix or leuprolide during the mail CS21 study (NCT00295750).</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 80 mg / Degarelix 80 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 160 mg / Degarelix 160 mg</title>
            <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O3">
            <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O4">
            <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Leuprolide participants who dropped out during the first year (i.e. during CS21) were all attributed to what became the leuprolide 7.5 mg / degarelix 160 mg arm.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Testosterone Level Maintained at &lt;=0.5 ng/mL From Day 28 in CS21 and Onwards</title>
          <description>The results below present the percentage of participants of having testosterone &lt;=0.5 ng/mL at each of the selected time points (there were more time points in the study) from Day 28 in CS21 (NCT00295750) until the end of the CS21A study.
In all treatment groups approximately 3% per year of the participants had at least one testosterone &gt;0.5 ng/mL during the study.</description>
          <population>CS21 ITT analysis set i.e. all participants who received at least one dose of degarelix or leuprolide during the mail CS21 study (NCT00295750).</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="96.5" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O3" value="98.6" lower_limit="90.2" upper_limit="99.8"/>
                    <measurement group_id="O4" value="97.6" lower_limit="92.7" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 364</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" lower_limit="93.5" upper_limit="98.8"/>
                    <measurement group_id="O2" value="98.3" lower_limit="94.8" upper_limit="99.4"/>
                    <measurement group_id="O3" value="97." lower_limit="88.9" upper_limit="99.3"/>
                    <measurement group_id="O4" value="96.0" lower_limit="90.5" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1876</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="72.7" upper_limit="88.4"/>
                    <measurement group_id="O2" value="87.7" lower_limit="78.0" upper_limit="93.3"/>
                    <measurement group_id="O3" value="84.1" lower_limit="70.2" upper_limit="91.9"/>
                    <measurement group_id="O4" value="88.4" lower_limit="75.5" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Testosterone From the Time of Switch From Leuprolide to Degarelix up to Day 56</title>
        <time_frame>From time of switch to Day 56</time_frame>
        <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide 7.5 mg/ Degarelix 240/80 mg</title>
            <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide 7.5 mg/ Degarelix 240/160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Testosterone From the Time of Switch From Leuprolide to Degarelix up to Day 56</title>
          <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" lower_limit="0.015" upper_limit="1.36"/>
                    <measurement group_id="O2" value="0.074" lower_limit="0.015" upper_limit="0.229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.084" lower_limit="0.015" upper_limit="0.23"/>
                    <measurement group_id="O2" value="0.068" lower_limit="0.015" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.076" lower_limit="0.015" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.066" lower_limit="0.015" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.085" lower_limit="0.015" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.073" lower_limit="0.015" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.074" lower_limit="0.015" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.074" lower_limit="0.015" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" lower_limit="0.015" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.077" lower_limit="0.015" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of PSA From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
        <time_frame>From time of switch to Day 56</time_frame>
        <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide 7.5 mg/ Degarelix 240/80 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide 7.5 mg/ Degarelix 240/160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of PSA From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
          <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="2938"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="1096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="754"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="1059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0" upper_limit="724"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="1422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="671"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="1567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0" upper_limit="441"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="2008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0" upper_limit="620"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="1926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
        <time_frame>From time of switch to Day 56</time_frame>
        <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide 7.5 mg/ Degarelix 240/80 mg</title>
            <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide 7.5 mg/ Degarelix 240/160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
          <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
          <units>International units/Liter (IU/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="1.12"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="0.035" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.035" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Follicle Stimulating Hormone (FSH) From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
        <time_frame>From time of switch to Day 56</time_frame>
        <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide 7.5 mg/ Degarelix 240/80 mg</title>
            <description>During the main CS21 study (NCT00295750), leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide 7.5 mg/ Degarelix 240/160 mg</title>
            <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Follicle Stimulating Hormone (FSH) From the Time of Switch From Leuprolide to Degarelix to Day 56</title>
          <population>All participants who received leuprolide in the main CS21 study (NCT00295750) and were switched over to degarelix in the CS21A extension study.</population>
          <units>International units/Liter (IU/L)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.2" upper_limit="15.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="1.5" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.8" upper_limit="11.1"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.5" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.7" upper_limit="11.8"/>
                    <measurement group_id="O2" value="2.6" lower_limit="0.4" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.15" upper_limit="7.9"/>
                    <measurement group_id="O2" value="2.3" lower_limit="0.15" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.15" upper_limit="7.6"/>
                    <measurement group_id="O2" value="1.7" lower_limit="0.15" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.15" upper_limit="6.7"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.15" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of CS21A and up to 4.5 years.</time_frame>
      <desc>The population comprised all participants who were enrolled into CS21A and who received at least one dose of degarelix during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 80 mg / Degarelix 80 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 160 mg / Degarelix 160 mg</title>
          <description>The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="E3">
          <title>Leuprolide 7.5 mg / Degarelix 80 mg</title>
          <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
        <group group_id="E4">
          <title>Leuprolide 7.5 mg / Degarelix 160 mg</title>
          <description>During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Retroperitoneal lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myopericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Inguinal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Scrotal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Prostate examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Colon cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Metastases to biliary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Metastases to penis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma unspecified histology indolent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Squamus cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Malignant lymphoma unclassifiable high grade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Squamus cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hyperkinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

